🇺🇸 FDA
Patent

US 9605263

Compositions for modulating C9ORF72 expression

granted A61PA61P21/00A61P21/02

Quick answer

US patent 9605263 (Compositions for modulating C9ORF72 expression) held by Ionis Pharmaceuticals, Inc. expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P21/00, A61P21/02, A61P25/00, A61P25/02